---
layout: post
title: "TG Therapeutics, Inc.; Withdrawal of Approval of New Drug Application for UKONIQ (Umbralisib Tosylate) Tablets, Equivalent to 200 Milligrams Base"
date: 2026-02-05 18:59:20 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-11631
original_published: 2022-05-31 00:00:00 +0000
significance: 8.00
---

# TG Therapeutics, Inc.; Withdrawal of Approval of New Drug Application for UKONIQ (Umbralisib Tosylate) Tablets, Equivalent to 200 Milligrams Base

**Published:** February 05, 2026 18:59 UTC
**Source:** Federal Register
**Original Published:** May 31, 2022 00:00 UTC
**Document Number:** 2022-11631

## Summary

The Food and Drug Administration (FDA or Agency) is withdrawing approval of the new drug application (NDA) for UKONIQ (umbralisib tosylate) Tablets, equivalent to (EQ) 200 milligrams (mg) Base, held by TG Therapeutics, Inc., 3020 Carrington Mill Blvd., Morrisville, NC 27560. TG Therapeutics, Inc. (TGT) has voluntarily requested that FDA withdraw approval of this application and has waived its opportunity for a hearing.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/05/31/2022-11631/tg-therapeutics-inc-withdrawal-of-approval-of-new-drug-application-for-ukoniq-umbralisib-tosylate)
- API: https://www.federalregister.gov/api/v1/documents/2022-11631

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
